Cigna covers approximately 18 million pharmacy benefit members through its pharmacy benefit manager, Evernorth (formerly Express Scripts). The Cigna-Evernorth relationship is the key to understanding GLP-1 coverage: Evernorth negotiates the formulary, sets prior authorization criteria, and manages step therapy protocols. Your Cigna medical plan and Evernorth pharmacy benefit work together to determine what you pay for GLP-1 medications.
Quick Answer
Cigna covers Ozempic and Mounjaro for type 2 diabetes on most plans. For weight management, Cigna/Evernorth has been selectively expanding GLP-1 coverage, with Zepbound gaining preferred status on several formulary options in 2026. Wegovy coverage varies by plan design. Foundayo is under formulary review and being added to select plans. Prior authorization is required for all GLP-1s, and Evernorth uses a structured step therapy approach.
Understanding Evernorth Formularies
Evernorth offers multiple formulary options to employers. The one your employer selected directly determines your GLP-1 coverage:
| Formulary Type | GLP-1 Coverage | AOM Coverage | Notes |
|---|---|---|---|
| National Preferred | Ozempic, Mounjaro preferred | Wegovy/Zepbound available on some | Most common employer formulary |
| Performance | Narrower selection; one preferred GLP-1 | Limited | Lower-cost formulary with fewer brand options |
| Basic | Ozempic or Mounjaro (not both) | Usually excluded | Most restrictive; aggressive generics-first |
| Custom Employer | Varies entirely | Varies entirely | Large employers negotiate their own terms |
The practical takeaway: if your employer chose the Performance or Basic formulary, weight-loss GLP-1 coverage may be excluded entirely regardless of medical necessity.
Medication-by-Medication Coverage
Ozempic (Semaglutide — Diabetes)
Ozempic is covered on most Cigna/Evernorth formularies for type 2 diabetes. It typically sits on Tier 2 (preferred brand) or Tier 3 (non-preferred) depending on the specific formulary. Prior authorization requires confirmed T2D diagnosis and documented metformin trial.
Wegovy (Semaglutide — Weight Loss)
Wegovy coverage on Cigna plans is employer-dependent. Evernorth offers an optional AOM rider that employers can add. Without this rider, Wegovy is excluded. Where covered, expect Tier 3 or specialty tier placement with strict PA criteria.
Zepbound (Tirzepatide — Weight Loss)
Zepbound has gained traction on Cigna/Evernorth formularies in 2026. Eli Lilly's aggressive rebate strategy has placed Zepbound in a preferred position over Wegovy on several Evernorth formulary options, making it the more accessible weight-loss GLP-1 for many Cigna members.
Foundayo (Orforglipron)
Foundayo is in the early stages of formulary inclusion. Evernorth has expressed interest in oral GLP-1 options as a cost-management strategy, and Foundayo's lower list price makes it an attractive formulary addition. Check with Cigna or Evernorth directly for your plan's current status.
Prior Authorization Criteria
For Diabetes GLP-1s
- Confirmed type 2 diabetes diagnosis (A1C ≥7.0% or documented T2D history)
- Trial of metformin for at least 90 days (or documented intolerance/contraindication)
- Some plans require trial of a second-line agent before GLP-1 approval
- Prescribed by an endocrinologist or primary care physician
For Weight-Loss GLP-1s
- BMI ≥30 kg/m², or BMI ≥27 kg/m² with a weight-related comorbidity
- Documentation of at least 6 months of structured weight management within the past 24 months
- Some formularies require trial of a non-GLP-1 AOM first (phentermine or naltrexone/bupropion)
- Must not be concurrently using another GLP-1 for a different indication
- Renewal at 6 months may require documentation of at least 5% body weight loss
Step Therapy Requirements
Evernorth's step therapy for GLP-1s is among the more structured in the industry:
Diabetes Pathway
- Metformin (first-line, 90 days minimum)
- Second oral agent — sulfonylurea, SGLT2 inhibitor, or DPP-4 inhibitor (some plans skip this step)
- GLP-1 agonist — the preferred GLP-1 on your formulary
Weight-Loss Pathway
- Structured lifestyle program (6 months documented)
- Non-GLP-1 AOM — phentermine, orlistat, or naltrexone/bupropion (required on some plans)
- GLP-1 agonist — must use the preferred option on the formulary
If your plan requires step 2 for weight loss and you have contraindications, your physician can request a step therapy exception with clinical documentation.
Appeals Process for Cigna/Evernorth Denials
Step 1: Internal Appeal
- File within 180 days of the denial
- Submit through myCigna.com, by phone, or by mail
- Include letter of medical necessity, clinical documentation, and guideline citations
- Cigna must respond within 30 calendar days for pre-service appeals
Step 2: Second-Level Internal Review
- Cigna offers a second internal review if the first appeal is denied
- A different reviewer examines the case
- Additional documentation can be submitted
Step 3: External Review
- Independent external review by a qualified third party
- Binding on Cigna
- Particularly effective when the denial appears to contradict clinical guidelines
Peer-to-Peer Review
Your physician can request a peer-to-peer review with an Evernorth clinical pharmacist or medical director at any point in the process. This is highly recommended as a parallel strategy — do not wait until the formal appeal process is complete to request it.
Cost Breakdown on Cigna Plans
| Medication | Preferred Tier | Non-Preferred Tier | Specialty Tier | Not Covered (Cash) |
|---|---|---|---|---|
| Ozempic | $30–$65 | $75–$175 | N/A | $935–$1,050 |
| Wegovy | $50–$90 | $100–$250 | 20–30% coinsurance | $1,300–$1,350 |
| Zepbound | $35–$80 | $80–$200 | 20–30% coinsurance | $1,060–$1,100 |
| Foundayo | $25–$55 | $55–$120 | N/A | $149–$299 |
Cigna-Compatible Savings Programs
- Cigna Patient Assurance Program: Caps out-of-pocket costs for certain medications — check if GLP-1s are included on your plan
- Manufacturer copay cards: Novo Nordisk and Eli Lilly savings programs stack with Cigna commercial coverage
- Evernorth Savings Assist: Automatic at the pharmacy counter for eligible members
- Foundayo launch pricing: Available for cash-pay and select insured patients
Maximizing GLP-1 Coverage on Cigna
- Identify your formulary type: Log into myCigna.com and check "Pharmacy" → "Drug costs" to see your formulary
- Choose the preferred GLP-1: If Zepbound is preferred over Wegovy on your plan, start there
- Evernorth mail order: 90-day supply through Evernorth/Express Scripts mail order often costs less per unit
- Ask about the AOM rider: If your employer plan excludes AOMs, ask HR about adding the rider at the next renewal
- Appeal denials: Cigna's denial rates for GLP-1s are among the higher in the industry, but appeal success rates are also meaningful — do not accept the first denial as final
Bottom Line
Cigna/Evernorth GLP-1 coverage in 2026 depends heavily on your employer's formulary choice. Diabetes coverage is solid. Weight-loss coverage is expanding, with Zepbound gaining preferred status on several formulary options. Step therapy is more aggressive than some competitors. The appeal process works, especially the peer-to-peer route. Foundayo's oral format and lower price point may create new coverage opportunities as Evernorth continues formulary updates.
Use MedSwitcher's tools to compare Cigna GLP-1 coverage with other insurers and find the most affordable path to your medication.
Sources
- Cigna pharmacy benefit information, 2026.
- Evernorth/Express Scripts formulary guidelines, Q1 2026.
- Cigna Clinical Coverage Guidelines: Anti-Obesity Pharmacotherapy.
- Obesity Medicine Association treatment algorithms, 2026.
- MedSwitcher insurance coverage database, updated April 2026.